Around 40% of new chemical entities fall into class II – low solubility drugs, making them difficult to formulate. Improving the bioavailability of these compounds is a major challenge but the technologies involved could help to extend the lifecycle of many medicines. Manufacturers are also looking to improve palatability and diversify drug delivery routes to increase patient compliance. Susan Birks spoke to Dr. Detlev Haack, Director Research & Development, and Dr. Thomas Hein, Director Sales & Business Development, both with HERMES PHARMA.
Download full version of the special report Problem-solving Ingredients for Complex Drugs (published in Manufacturing Chemist, 01/2013)